U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Eli Lilly & Companies investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.
Safety and effectiveness of this investigational therapy continues to be evaluated. Bamlanivimab was shown in clinical trials to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo.
https://www.nextbigfuture.com/2020/11/eli-lilly-covid-antibody-treatment-gets-emergency-fda-authorization.html
Filed under: #!!# |
Hans Howe 